Program
nuzefatide pevedotin
Also written as “BT5528”, “nuzefatide pevedotin (BT5528)” and “Nuzefatide pevedotin”.
Its studies are mostly in Ovarian Neoplasms · Pancreatic Neoplasms, led by BicycleTx.
Furthest: phase 2, since Nov 19, 20193 company-led studies, 3 open or runningNext primary completion: Dec 31, 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BicycleTx | 33 open or running | phase 2since Nov 19, 2019 | Nov 19, 2019 | Dec 31, 2026phase 2 · NCT04180371 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 19, 2019First study: phase 2 study in Ovarian NeoplasmsFirst studyNCT04180371 · 288 enrolled · United States, Belgium, South Korea and more
- Feb 26, 2026Phase 2 study in Pancreatic NeoplasmsNCT07450859 · 39 planned · United States, South Korea
- Jun 26, 2026Phase 2 study in Advanced Solid TumorsNCT07681674 · 16 planned
Ahead
- Dec 31, 2026Primary completion: phase 2 study in Ovarian NeoplasmsNCT04180371
- Mar 2029Primary completion: phase 2 study in Pancreatic NeoplasmsNCT07450859
- May 30, 2030Primary completion: phase 2 study in Advanced Solid TumorsNCT07681674
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07681674Advanced Solid Tumors | 2 | Not yet recruiting | May 30, 2030 | 16 |
| NCT07450859Pancreatic Neoplasms · United States, South Korea | 2 | Recruiting | Mar 2029 | 39 |
| NCT04180371Ovarian Neoplasms · United States, Belgium, South Korea and more | 2 | Active, not recruiting | Dec 31, 2026 | 288 |
How it is read
Names in the registry
- “BT5528”, 1 entry
- “nuzefatide pevedotin (BT5528)”, 1 entry
- “Nuzefatide pevedotin”, 1 entry
Conditions, from the studies’ own filings
- Ovarian Neoplasms, 1 study
- Pancreatic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.